MedPharm moves into $4M expansion of its North Carolina facility

5 Dec 2019

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

MedPharm, experts in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina.

MedPharm moves into $4M expansion of its North Carolina facility

The $4-million expansion has tripled the facility’s footprint to approximately 25,000 sq. ft significantly expanding capacity and supporting MedPharm’s continued commitment to the topical and transdermal market.

Investment into the site was made following increased demand for MedPharm’s topical and transdermal services. The expansion covers pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering. In addition, the new space will include dedicated innovation, microbiology and histology laboratories.

“We are excited to be able to offer an expanded and unmatched level of services from our facility in the North Carolina Research Triangle Park area”, commented Eugene Ciolfi MedPharm’s President and CEO. “The expanded space has a streamlined workflow that segregates phases of work and makes transition through each project more efficient with complimentary equipment positioned where it’s most needed.”

The new laboratory expands capacity for MedPharm’s proprietary models which de-risk its customers’ development programs as it accommodates automated and high throughput analytical instrumentation to improve turnaround times and elevate the consistent quality of data for clients.

The facility’s unique, dedicated innovation Lab will allow MedPharm to continue its pioneering approach to the development of custom performance testing models to meet unmet customer needs in the topical and transdermal markets. This investment also means that MedPharm can react quickly to solving project-specific problems for its customers and stay at the forefront of the latest scientific breakthroughs and technology.

The expansion will also create over 100 new highly skilled scientific and strategic positions in Research Triangle Park in North Carolina.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more